OR WAIT null SECS
January 04, 2023
Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.
January 03, 2023
Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.
Experts weigh in on trends in the biotechnology market, psychedelics, and India.
January 02, 2023
Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”
Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.
December 19, 2022
GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.
AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
December 14, 2022
Under the collaboration between Vertex and Entrada, the companies will work on discovering and developing intracellular endosomal escape vehicle therapeutics for myotonic dystrophy type 1.
December 13, 2022
Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.
Takeda will purchase the rights to Nimbus Pharmaceuticals candidate, NDI-034858, which is currently being evaluated for treating multiple autoimmune diseases.